Reminding staff of diligence during the medication process is not enough to ensure safety: Learning from wrong fluid product selection incidents in the care of critically ill patients

Minna Kurttila a,b,⁎, Susanna Saano b, Raisa Laaksonen a

a Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Finland
b KUH Pharmacy, Hospital Pharmacy of Kuopio University Hospital (KUH), Finland

ARTICLE INFO

Keywords: Fluid therapy Wrong fluid product Voluntary incident reporting Intensive care unit ICU

ABSTRACT

Background and objectives: Wrong fluid product selection may cause harm to patients. This study aimed to describe voluntarily reported wrong fluid product selection incidents, including their consequences, the reported latent conditions and active failures leading to these and the suggested safeguards to improve the fluid therapy safety within the intensive care (ICU) environment.

Methods: All voluntarily and anonymously reported wrong fluid product selection incidents in all Finnish ICUs during 2007–2017 were reviewed. The incident reports included categorized data that were analyzed quantitatively, and narratives that were analyzed qualitatively, using content analysis. The results were reported as frequencies and percentages and described by using Reason’s model of human error.

Results: Over the eleven years, one wrong fluid product selection incident was reported every six days (n = 663; 584 errors, 79 near misses); most were reported to have occurred during the dispensing/preparing phase (92%). Of the 584 reported selection errors, a quarter (26%) was reported to have caused consequences to patients, and one third (35%) to have required corrective or monitoring actions. The main reported latent conditions to the incidents were Working environment and resources (e.g. workload and time pressure) (29%), Similar-looking and -sounding names or shared features of the product containers (i.e. the LASA phenomenon) (28%) and Working methods (22%); and the main reported active failures were a lack of concentration, or forgetfulness (26%). Some usable suggestions of safeguards were made, e.g. optimizing fluid storage (15%) or utilizing checking practices (21%). While requiring accuracy, i.e. reminding staff of diligence and to be more attentive to detail during the whole medication process, was emphasized in most reports (71%), involving manufacturers in redesigning labels of fluid products, utilizing technology and strengthening pharmacy services are advocated existing literature.

Conclusions: Wrong fluid product selection incidents with various latent conditions and active failures were reported more than once a week. To minimize the serious LASA phenomenon, multi-professional collaboration, coordinated international discussion and agreements of solutions with manufacturers, regulators and end-users, are needed. However, work is also needed to reduce the other latent factors, such as Working environment and resources as well as cognitive biases in daily work that may contribute to the occurrence of LASA related errors.

1. Introduction

For more than a century, fluid therapy has been in clinical use.1–2 In the treatment of a critically ill patient, different fluid products are used to correct intravenous volume deficiency or acute hypovolemia, to compensate for existing or developing deficiencies, and to maintain daily needs. They are also used to dilute medicines and, in small amounts, to keep vascular catheters open. Improper fluid selection cause to contribute to the patient: changes in blood glucose; electrolyte disturbances; hyperchloremic metabolic acidosis; and renal failure requiring dialysis, increasing morbidity and mortality.1 To provide optimal care for patients, intravenous fluids should be treated with the same intensity as other medications, as they have specific indications, contraindications and adverse effects.1,2 Medical expertise is required to select the right treatment, considering individual patient factors and other treatments. Moreover, critical care nurses have an important role in implementing and monitoring safe fluid therapy4 and pharmacists have unique expertise to optimize fluid therapy.1,2,5 In Finnish intensive care units (ICUs), physicians are responsible for prescribing and nurses for dispensing/preparing and administering fluid therapy. While in some ICUs pharmacists mainly maintain medicine stocks and

⁎ Corresponding author at: KUH Pharmacy, Hospital Pharmacy of Kuopio University Hospital (KUH), PL 100; 70029 KYS, Finland.
E-mail address: minna.kurttila@kuh.fi (M. Kurttila).

http://dx.doi.org/10.1016/j.rcsop.2022.100181
Received 30 November 2021; Received in revised form 27 July 2022; Accepted 19 September 2022
Available online xxxx
2667–2766/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
prepare medicines, they are gradually gaining specialist roles in clinical pharmacy in multidisciplinary teams to improve medication safety.\(^6\)

Only some cases of fluid product selection errors have been reported.\(^3\) Similar-looking and -sounding names (Look-Alike and Sound-Alike or LASA) or shared features of the product containers may contribute to selection errors; up to 33% of reported medication errors may be caused by packaging and labelling confusion and up to 25% by name confusion, all of which poses a significant threat to patient safety.\(^3\) The current guidelines of the Finnish Medicines Agency\(^5\) and European Commission\(^6\) for the naming, packaging and labelling of medicines consider some patient safety factors, such as instructions for the naming of the medicine and the information content of the labels. However, they do not appear to consider all human factors, which the then National Patient Safety Agency, which merged with the National Health Service (NHS) NHS in 2019, drew attention to while making recommendations to the healthcare industry for the designing, labelling, and packing of injectable drugs, including fluid products\(^7\). Recently in the US, The Institute for Safe Medication Practices (ISMPI, 2021) has voiced concerns about recurring incidents involving confusion about similar appearances of labelling and packaging of premixed and base solutions, in which manufacturers have a key role to improve fluid therapy safety.\(^7\) Protective structures for this and other factors, contributing to wrong fluid product selection incidents, should be developed, so that the World Health Organization’s (WHO 2021) Global Patient Safety Action Plan to eliminate avoidable risks and harms to patients in healthcare,\(^8\) is also applied to fluid therapy.

The use of voluntary incident reporting systems to aggregate incident reports at the national level enables identifying, and learning from, the risks and contributing factors of rare incidents, which may not be easily reported at the national level enables identifying, and learning from, the risks and contributing factors of rare incidents, which may not be easily reported. Firstly, the study aimed to describe the voluntarily reported fluid selection incidents, the fluid products involved, the reported consequences of these incidents, the actions taken to alleviate or monitor the consequences, and the phases of medication process at which the incidents had been reported to have occurred. Secondly, the aim was to describe the reported latent conditions and active failures of incidents, the safeguards the members of staff had suggested to be implemented to improve medication safety, and to compare these suggestions with existing literature. To our knowledge, there are no previous studies concerning wrong fluid product selection incidents within the ICU environment at the national level.

2. Methods

This retrospective mixed-methods study examined all wrong fluid product selection incidents including both errors and near misses, reported voluntarily and anonymously by healthcare professionals (rapporteurs) to the national reporting system from all adult and paediatric intensive care and high dependency units (ICUs) in all healthcare districts (n = 20) in mainland Finland during 2007–2017. In this study, wrong fluid product selection incident means prescribing (physicians), dispensing/preparing (mainly nurses and in some ICUs pharmacists during office hours) or administering (mainly nurses and sometimes physicians) of a wrong fluid product.

To obtain the data from the administrator, research permissions were obtained separately from each healthcare district for the 2007–2014 data set (2007 was a pilot year), and centrally from the Finnish Patient Safety Association for 17 districts and separately from three others that are not members of the Association for the 2015–2017 data set. An ethical review was not required as no identifiable patient information is included in the reports.

The administrator of the national reporting system, Awanic Ltd., provided all medication related incident reports of the ICUs in Microsoft Excel\(^®\) spreadsheets to the first author (MK). In the national reporting system, structured reporting of medications involved in incidents has been possible since 2015\(^15\),\(^16\); previously, they had been reported in the narratives that were used to identify medications involved in the incidents by the first author (MK) who discussed unclear cases with the second author (SS). All incident types related to fluid products were identified manually, and after which the wrong selection of fluid product incidents were identified manually and included in this study. The incident reports included categorized data reported voluntarily by rapporteurs and completed locally by classifiers, mainly head nurses in ICUs, and narrative descriptions of the incidents reported by the rapporteurs.

The study employed both quantitative and qualitative analysis. Quantitative descriptive analyses were performed to the categorized data, such as the fluid products involved, nature of incidents (both errors and near misses), consequences to the patients, the phases of the medication process at which the incidents had been reported to have occurred, and latent conditions. The first author (MK) reviewed the original categorizations of the incidents independently and used the narrative descriptions of the incidents to supplement the categorizations, and both were described separately in the results. All unclear reports were discussed with the second author (SS) to reach consensus. Categorized latent conditions, and active failures within the medication process were illustrated onto Reason’s model by all authors.

For this study, the fluid products involved in the incidents were categorized according to the Anatomical Therapeutic Chemical (ATC) Classification system: Electrolyte solutions; Electrolytes with carbohydrate solutions, Blood substitutes and plasma protein fractions (Colloids), Other blood products (Blood products) and IV solution additives (e.g. Electrolyte concentrates, vitamins). The following groups were added: parenteral and enteral nutrition were combined and named as Nutritions; Peritoneal dialysis, haemodialysis and haemofilters were combined and named Dialysis; and the Special fluids group contained e.g. ready-to-use heparinized solution only used in the cannula flush system, sterile water, and sodium bicarbonate.

The classifiers had categorized the consequences of the incidents to patients as minor (a mild harm demanding little or no treatment), moderate (a harm demanding treatment) and major (a harm impairing the patient’s quality of life or requiring life-sustaining care). They had also categorized the latent conditions of the incidents (Table 1) as well as proposed prevention measures or safeguards in the following categories: informing others or discussing what had happened; involving management at a higher level required; planning a development measure required; or no action required. Multiple latent conditions or safeguards could have been reported for each fluid selection incident.

Descriptive statistical analyses were conducted using Microsoft Excel\(®\); the results are reported as frequencies, percentages and medians.

Additionally, qualitative abductive content analysis\(^18\) of the narratives was performed to identify and categorize the described consequences to patients; actions taken to alleviate or monitor them; any external or local latent conditions, and active failures; as well as safeguards to prevent similar incidents from occurring. The first author (MK) read repeatedly all
which were discussed with all authors to reach consensus. Thereafter, the narrative descriptions, analyzed and preliminarily categorized them, all of them.

| Working methods                  | Working methods and procedures |
|----------------------------------|--------------------------------|
|                                  | Availability and use of instructions related to the task |
|                                  | Decision making tools          |
| Working environment and resources | Workload, shift arrangements, time pressure |
|                                  | Number and qualification of staff |
|                                  | Physical working environment   |
|                                  | Problems with the operation and use of patient and other information systems |
| Communication                    | Insufficient use of available information |
|                                  | Verbal or written communication incomplete or unclear |
|                                  | Knowledge, skills and competence |
|                                  | Availability and adequacy of training and guidance |
| Medications                      | Generic medicines |
|                                  | Teamwork |
|                                  | Work supervision |
|                                  | Cooperation, division of work and support |
| Equipment and supplies           | Availability and placement of a device |
|                                  | Availability of equipment and supplies (ergonomics) |
| Organization and management      | Operating principles and management practices |
| Patient and relatives            | Severity of the disease |
|                                  | Unknown or no categorized factors |

Table 1 Categorized latent conditions of the incidents and examples of them.

Table 3 shows the categorization of the latent conditions and the examples of them. There are a total of 7623 medication related incident reports, of which 2089 concerned fluid therapy, including errors (reached the patient) and near misses (did not reach the patient), were voluntarily reported by healthcare professionals in ICUs during 2007–2017. Duplicated reports (n = 5) and inadequate reports (reports did not describe an actual incident) (n = 34) were excluded, and reports, in which more than one incident had been reported, were divided into separate reports (n = 151), resulting in 2201 incident reports: on average, one fluid therapy incident was reported every other day. Of these, 663 (30%) were related to wrong fluid selection

3. Results

A total of 7623 medication related incident reports, of which 2089 concerned fluid therapy, including errors (reached the patient) and near misses (did not reach the patient), were voluntarily reported by healthcare professionals in ICUs during 2007–2017. Duplicated reports (n = 5) and inadequate reports (reports did not describe an actual incident) (n = 34) were excluded, and reports, in which more than one incident had been reported, were divided into separate reports (n = 151), resulting in 2201 incident reports: on average, one fluid therapy incident was reported every other day. Of these, 663 (30%) were related to wrong fluid selection (Fig. 1): on average, one incident was reported every six days; most had reached the patient (n = 584, 88%). During the first pilot year, only four wrong fluid selection incidents were reported. Thereafter, the median was 59 (IQR 41.0–66.5) wrong fluid product selection incident reports annually during the first five years (2008–2012), and 78 (IQR 67.5–86.0) during the last five years (2013–2017) of data collection, respectively.

3.1. Wrong fluid product selection incidents by fluid groups

The most frequently reported selection incidents occurred between Electrolyte solutions (n = 116, 18%) (Table 2); most often between Sodium chloride 9 mg/ml and Ringer’s acetate solutions (n = 81). The second most commonly reported selection incidents occurred between IV solution additives (n = 78, 12%); mostly between Potassium chloride and Potassium phosphate concentrates (n = 30) and between Potassium and Sodium chloride concentrates (n = 25), and between Nutritions (n = 78, 12%); mostly between Nutritions with an identical brand name but different specific characteristics (n = 68) (Fig. 2).

3.2. Reported consequences and correcting actions of fluid product selection errors

Almost one fifth (n = 110, 19%) of the 584 reported errors had been categorized to have caused consequences to patients (Table 2). While the classifiers had recorded “no consequences” or consequences “not known” to patients in 39 incident reports, the rapporteur had described consequences to patients in the narrative of these reports. Thus, at least one quarter (n = 149, 26%) of the reported errors had resulted in consequences to patients, of whom one died. According to the narratives, the most common consequences of the errors to patients were blood glucose changes (n = 49), electrolyte disturbances (n = 38) and haemodynamic changes (n = 13). Furthermore, a third of the incidents (n = 202, 35%) had been reported to have required some corrective action to alleviate the consequences (i.e. additional treatments or medicines, or monitoring of, patients), to alleviate the consequences to the patient.

Fig. 1. Flowchart of identifying the voluntarily reported wrong fluid product selection incidents in all ICUs in Finland (2007–2017) and their rapporteurs by profession.
Table 2
Reported wrong fluid selection incidents by fluid groups (n = 663) with the nature of the incidents, the categorized consequences to patients, the described consequences to patients, and the described correcting and monitoring actions.

| Reported selection incidents by fluid groups | Nature of the incident, n | Categorized consequences to the patients, n | Consequences to the patients described in the narratives, n | Correcting and monitoring actions taken after the incident described in the narratives, n |
|---------------------------------------------|---------------------------|--------------------------------------------|--------------------------------------------------|----------------------------------------------------------------------------------|
|                                             | Error | Near | miss | Total | Major | Moderate | Minor | None | Not known | Total | Treatment* | Monitoring with additional laboratory test(s) | Administering additional medicine(s) | Total |
| Between Electrolyte solutions               | 112   | 4    | 116  | 0     | 0     | 11      | 80    | 25   | 116       | 8     | 0          | 10                                           | 3                                         | 13    |
| Between IV solution additives               | 65    | 13   | 78   | 1     | 0     | 11      | 53    | 13   | 78        | 12    | 1          | 19                                           | 0                                         | 20    |
| Between Nutritions                          | 76    | 2    | 78   | 0     | 1     | 9       | 53    | 15   | 78        | 6     | 1          | 4                                            | 1                                         | 6     |
| Between Carbohydrate solutions              | 70    | 4    | 74   | 0     | 4     | 17      | 40    | 13   | 74        | 25    | 0          | 32                                           | 18                                        | 50    |
| Between Electrolyte solutions and Electrolytes with carbohydrate solutions | 60    | 5    | 65   | 0     | 1     | 14      | 41    | 9    | 65        | 22    | 0          | 23                                           | 12                                        | 35    |
| Between Blood products                      | 15    | 35   | 50   | 1     | 0     | 3       | 39    | 7    | 50        | 2     | 2          | 3                                            | 2                                         | 7     |
| Between Electrolytes with carbohydrate solutions | 44    | 3    | 47   | 0     | 0     | 3       | 33    | 12   | 47        | 3     | 0          | 7                                            | 0                                         | 7     |
| Between Fluid Products and Drug infusions   | 44    | 1    | 45   | 1     | 2     | 13      | 21    | 8    | 45        | 19    | 0          | 10                                           | 14                                        | 24    |
| Between Special fluids and Fluid Products   | 29    | 3    | 32   | 0     | 0     | 2       | 8     | 22   | 32        | 2     | 0          | 4                                            | 1                                         | 5     |
| Between Dialytics                           | 19    | 1    | 20   | 0     | 0     | 4       | 15    | 1    | 20        | 7     | 0          | 11                                           | 2                                         | 13    |
| Between Carbohydrate and Electrolytes with carbohydrate | 19    | 1    | 20   | 0     | 0     | 2       | 16    | 2    | 20        | 4     | 0          | 5                                            | 2                                         | 7     |
| Between Electrolyte solutions and IV solution additives | 6     | 6    | 12   | 0     | 0     | 3       | 9     | 0    | 12        | 3     | 0          | 4                                            | 4                                         | 8     |
| Between Electrolyte solutions and Carbohydrate solutions | 9     | 1    | 10   | 0     | 0     | 1       | 8     | 1    | 10        | 1     | 0          | 1                                            | 0                                         | 1     |
| Between Colloids                            | 8     | 0    | 8    | 0     | 0     | 3       | 5     | 0    | 8         | 1     | 0          | 1                                            | 1                                         | 1     |
| Between Others**                           | 8     | 0    | 8    | 0     | 0     | 3       | 2     | 3    | 8         | 4     | 0          | 3                                            | 2                                         | 5     |
| Total                                      | 584   | 79   | 663  | 3     | 8     | 99      | 422   | 131  | 663       | 119   | 4          | 136                                          | 62                                        | 202   |

* Treatments included cannula-related procedures, administration of excess oxygen, haemodialysis and resuscitation.

** Between Others included wrong selection of fluids between Colloid and electrolyte solutions (n = 2), Colloid and Electrolytes with carbohydrates (n = 1), Nutrition and Electrolyte solution (n = 1), Nutrition and Electrolytes with carbohydrates (n = 1) and between Citrates and IV solution additives (n = 3).
3.3. Reported latent conditions in wrong fluid selection incidents and safeguards to prevent them

The manufacturers (n = 183, 28%) as the designers of the fluid product names, labels and packaging (i.e. the LASA phenomenon), and hospital pharmacies (n = 22, 3%) responsible for the procurement of medicinal products, were identified to be responsible for the external latent conditions for wrong fluid selection incidents (Fig. 3). Similar names or packaging of fluids had explicitly been mentioned in 144 (21%) narratives of the reports. In addition to that, in another 43 reports, the problem with similar names or packaging had implicitly been described through recommending optimizing the safe storage of fluids to prevent the occurrence of mix-ups between fluid products. Thus, the LASA phenomenon was involved in almost one third of the reported incidents (n = 187, 28%); the median was 14 (IQR 8.5–19.0) LASA phenomenon reports annually during the first official five years (2008–2012), and 25 (IQR 18.0–28.5) during the last five years (2013–2017) of data collection, respectively. As a safeguard, some rapporteurs proposed that the names and appearances of the fluid products should be redesigned (n = 58).

The most typical categorized local latent conditions for wrong fluid product selection incidents were Working methods (n = 147, 22%), followed by Working environment and resources (n = 62, 9%), Communication (n = 57, 9%) and Education, induction and competence (n = 48, 7%) Additionally, in another 129 narratives conditions related to the Working environment and resources, such as time pressure, workload, staff shortages, multitasking, interruptions, insufficient lighting were described, so the Working environment and resources accounted for almost one third of the reported incidents (n = 191, 29%). Similarly, in another 77 narratives conditions related to Education, induction and competence were described, increasing its share to almost one-fifth (n = 125, 19%). Finally, descriptions related to Communication were mentioned in another 18 narratives, increasing it to 11% (n = 75).

Most frequently the classifiers had proposed to prevent the recurrence of similar incidents by informing others or discussing what had happened (n = 481, 73%) and often thought that no action was required (n = 125, 19%). However, in the narratives, the rapporteurs had most commonly suggested education (n = 59, 9%) as a safeguard.

3.4. Reported active failures in wrong fluid selection incidents and safeguards to prevent them

Wrong fluid product selection incidents were reported to have occurred mainly during the dispensing/preparing phase (n = 607, 92%) of the medication process, followed by the administration (n = 35, 5%) and prescribing phase (n = 21, 3%) (Fig. 3).

In the narratives, the rapporteurs, had described e.g. a lack of concentration, or forgetfulness (n = 170, 26%) and physical feelings of tiredness or sickness (n = 18, 3%). To counteract these, the rapporteurs and classifiers had suggested safeguards known to them: requiring accuracy, i.e. reminding staff of diligence and to be more attentive to detail during the whole medication process, was mentioned as a safeguard. Comparing these safeguards with those found in existing literature, showed a disparity; according to the literature safety within the fluid therapy processes should be improved by utilizing more extensively protective safeguards, which is also in line with the WHO Global Plan of Action on Patient Safety.12

4. Discussion

4.1. Results overview

In this national study covering all Finnish ICUs from 2007 to 2017, one wrong fluid product selection incident was, on average, reported every six days. While the reporting activity of these incidents seemed to have reached a plateau during the last five years of the study, only a fraction of medication incidents can be identified through voluntary reporting.31 Most incidents were reported to have occurred during the dispensing/preparing phase. In Finland, nurses are mainly responsible for dispensing/preparing medicines, including fluids; a task for which hospital pharmacists or technicians could offer their expertise.23 The most frequently reported wrong selection incidents occurred between Electrolyte solutions, between IV solution additives and between Nutritions; the latter two groups include high-alert medications, potassium concentrates and parenteral nutrition, that may cause significant harm to the patient, if used in error.32 At least a quarter of the reported fluid selection errors led to consequences for patients. To prevent the recurrence of such incidents, the rapporteurs and classifiers had made some usable suggestions, e.g. optimizing fluid storages or employing double-checking of fluids, using checklists and shift changing checks, but most often the need for requiring accuracy, i.e. reminding staff of diligence and to be more attentive to detail during the whole medication process, was mentioned as a safeguard. Comparing these safeguards with those found in existing literature, showed a disparity; according to the literature safety within the fluid therapy processes should be improved by utilizing more extensively protective safeguards, which is also in line with the WHO Global Plan of Action on Patient Safety.12

In this study, the LASA phenomenon and Working environment and resources were both identified in nearly a third of the wrong fluid product selection incidents as latent conditions, followed by Working methods and Education, induction and competence, both in one-fifth of the incidents. These latent conditions, especially overburdened staff; as well as psychological aspects, like cognitive biases, may further contribute to the LASA phenomenon.7 Confusion is compounded by similarities in the spelling of the names of medicines, especially, if sharing at least three identical letter strings or groups of letters at the beginning of the names35; as well as similarities in the infusion bags with a transparent bag, clear fluid and black labelling. Estock et al. (2018) have shown in high-fidelity clinical simulation, that selection errors may be reduced by using redesigned labels to identify and select the right intravenous bag.34

The findings of this study related to the fairly stably reported LASA phenomenon, the recommendations of the then NPSA on designing medicine packaging and labelling,10 and the intentions of the ISMP to launch discussions with regulators and manufacturers on the LASA risks with premixed and base solutions,11 show that the LASA phenomenon of fluid products is worldwide. Thus, developing safe product names and readable labels and barcodes should take place both at national and international levels, between medication safety organizations, manufacturers, regulators and end-users to find solutions to ensure safe identification of the products at all phases of the fluid therapy process.11,20

At the organizational level, the wrong fluid product selection errors should also be prevented. Hospital pharmacies should consider, in addition to prices, safety management in the medicine procurement process by avoiding LASA medicines and favouring barcodes on the primary drug packaging.30 They could also offer re-packaging and attaching extra stickers on the packaging26; using different typographical strategies (e.g. TALLman Lettering),20,21 and inform healthcare professionals about changes in the formulary.30

When developing safeguards, the working environment, working methods, by utilizing organized fluid storages,7,11,21 double-checking policies,5,7 or technology, e.g. using bar coding during dispensing22 and administering,20,21 to verify right fluid product, as well as the individuals and their activities should also be taken into account. Cognitive biases, errors or distortions in decision-making, are increasingly recognized as contributors to patient safety incidents.16 Person-, patient- and system-related factors, such as excessive workload, work-related stress, lack of resources, and complexity of tasks, observed also in this study, may expose, or increase the probability of, cognitive biases. Thus, it is important for organizations to gain knowledge about cognitive biases and the factors
Fig. 3. Triangle of reported latent conditions and active failures in different parts of medication process related to wrong fluid product selection incidents, surrounded by safeguards identified in the narrative descriptions of incident reports (on the left of the triangle) and existing literature (on the right of the triangle).2,3,5,7,10,11,13,20–30 More than one latent condition or safeguard suggestion could have been reported for each fluid selection incident.

Abbreviations: CPOE, Computerized Physician Order Entry; CDSS, Clinical Decision Support System; BMCA, Bar Code Medication Administration; ADC, Automated Dispensing Cabinet; Closed Loop EMMS, Closed Loop Electronic Medication Management Systems; and LASA, Look Alike and Sound Alike medications.
affecting them. Further, improving work system conditions, such as investing in the well-being of healthcare personnel and strategies to reduce work-related stress, optimizing the physical work environment, ensuring adequate staffing and expertise and regular training on medicines, are crucial strategies to reduce errors in general.

Hospital pharmacies in turn, can improve medication safety in ICUs by optimizing and maintaining fluid storage and offering drug stock refilling service provided by pharmacy technicians. Under the supervision of pharmacists, appropriately trained technicians could be involved in dispensing and preparing medicines to patients, which is already practice in several countries.26 Such skill-mix allows pharmacists to devote time to clinical pharmacy services,22 such as working in a team with prescribers and nurses, conducting medication and fluid product prescription reviewing,13 and building and implementing strategies for safer medication processes,13 as recommended by the European Association of Hospital Pharmacy.36

Some of the safety measures mentioned above may be complex interventions requiring changes in organizations and time for practical implementation. Therefore, risk management activities should be well-coordinated and adequately resourced with clear responsibilities with expert understanding of medication safety, as development work must be continuous. At the organizational level, such a task could be given to Medication Safety Officers (MSO)27 or IV Fluid Coordinators28 responsible for safe fluid therapy training, reviewing IV fluid related incident reports, and implementing evidence-based best practices in IV fluid therapy processes. They could also develop guidance for safe fluid therapy practices at the national or international levels (e.g. to tackle the LASA phenomenon as a medication safety risk with the contribution of the regulators and manufacturers). In Finland, the first MSO was employed in one of the Healthcare districts in 2017; their number has since increased.

4.3. Strengths and limitations

This study included all fluid selection incident reports from all Finnish ICUs on the mainland during eleven years. Data aggregation was employed to uncover systematic failures of certain incidents that are not easily identifiable at the local level.13 Another strength of this study was the analysis of both the structured categorized data and the free-text narratives of the incident reports. These together provided a comprehensive picture of some of the points of risk associated with wrong fluid product selection incidents, for which system based safeguards should be developed to prevent further errors. It should be noted that while the analysis of qualitative data (i.e. the narratives) is influenced by the backgrounds of the researchers,19 steps were taken to ensure rigorous and credible analysis. To confirm objectivity, the categorizations used in the analysis were agreed upon with all authors and any ambiguities were discussed with the second researcher. While independent qualitative analysis of the narrative data by two researchers could have improved the reliability of the analysis, the researchers’ experience and expertise in hospital pharmacy and in research may be seen as strengthening factors in objective analysis.

Voluntary incident reporting systems have limitations, such as underreporting31 and variations in the quality of categorizing,14 the latter strengthening factors in objective analysis.

5. Conclusions

The study showed that wrong fluid product selection incidents were reported frequently, and both latent conditions and active failures were present in the incidents. To minimize the serious LASA phenomenon, multi-professional collaboration, coordinated international discussion and agreements of solutions with manufacturers, regulators and end-users, are needed; however, work is also needed to reduce the other latent factors, such as working environment and resources as well as cognitive biases in daily work that may contribute to the occurrence of LASA related errors.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We warmly thank the state research funding and Kuopio University Hospital Research Foundation for their financial support for the study.

References

1. Malbrain M, Langer T, Anneau D, et al. Intravenous fluid therapy in the perioperative and critical care setting: executive summary of the international fluid academy (IFA). Ana Intensive Care 2020;10. https://doi.org/10.1111/1746-159X.12702.36. Wilkinson JN, van Haren FMP, Malbrain MLNG. Intravenous fluids: Do not drown in confusion. Vincent J. Annual Update in Intensive Care and Emergency Medicine. Switzerland AG: Springer Nature; 2020. p. 153-172.

2. Woodcock TE, Cook TM, Gupta KJ, Hartle A. Arterial line blood sampling: preventing hypoglycaemic brain injury 2014: the Association of Anaesthetists of Great Britain and Ireland. Anaesthesia 2014;69:380-385. https://doi.org/10.1111/anae.12536.

3. Barlow A, Barlow B, Tang N, Shaw BM, King AE. Intravenous fluid management in critically ill Adults: a review. Crit Care Nurse 2020;40:e17-e27. https://doi.org/10.4037/ccn2020337.

4. Hawkins WA, Butler SA, Poirier N, Wilson Jr CS, Long Jr MK, Smith SE. From theory to bedside: implementation of fluid stewardship in a medical ICU pharmacy practice. Am J Health Syst Pharm 2021. https://doi.org/10.1093/ajhp/zxab453.

5. Schepel I, Aronpuro K, Kvanström K, et al. Strategies for improving medication safety in hospital: evolution of clinical pharmacy services. Res Soc Adm Pharm 2019;15.873-873.6 4

6. Berman A. Reducing medication errors through naming, labeling, and packaging. J Med Syst 2004;28:8-29. https://doi.org/10.1023/b:joms.0000021518.6070y.10.

7. Finnish Medicines Agency. Labelling and package leaflets for medicinal products. https://www.emea.europa.eu/en/news/160140/764653/M%C3%A4%C3%A4r%C3%A4%C3%A4ys+3_2019+L%C3%A4%C3%A4kevalmistein+%40+myyntin-%C3%A4%C3%B8ys+3+2019+1+C%C3%A4+4%C3%A4velinnist%C3%A4n+m+yssynin%25+C%A4%25+C%40lymermin%25+C%A4+ja+a+pakkauslento+FL+pdf/cb2135db-e26a-f7bc-a816-04a27495285.2019. (accessed 10 July 2022).

8. European Commission. Guidance on the readability of the labelling and package leaflet of medicinal products for human use, revision 1. http://ec.europa.eu/health/files/eudract/vol-2/c/2009_01_12 readability_guideline_final_en.pdf 2009. (accessed 9 January 2021).

9. National Patient Safety Agency. Design for Patient Safety: A guide to labelling and packaging of injectable medicines. https://www.intmedsafe.net/wp-content/uploads/2014/01/0592_Injectablesbook9_Vehlki.pdf 2008. (accessed 21 August 2020).

10. Institute for Safe Medication Practices, (ISMP). Updated Guidance Needed for Longstanding Large Volume Parenteral (LVP) Labeling and Packaging Problems.
